Clinical Trials Logo

Clinical Trial Summary

Recurrent abdominal pain affects up to 37% of school-age children, mostly girls. These problems results in decreased quality-of-life, absence from school, lower sleep quality and increased health-care consumption. Long-term effects are lasting pain-symptoms and increased risk for psychiatric illness. The scientific evidence for interventions towards long-term pain in children is limited and pharmacological treatment is not effective. Cognitive behavioral therapy has shown some effect but is time- and resource consuming. Dance and yoga can enhance positive protective factors through better body awareness and increased self-regulation. Relaxation in yoga also has positive effect on abdominal pain. The aim of this study is to evaluate the effects of an intervention with dance and yoga for girls, 9 to 13 years old, with recurrent abdominal pain. The participants will be identified through pediatric clinics in Örebro County, primary health care and school health care. They will be randomized to intervention with weekly dance- and yoga class for 8 months or control group with standard treatment. Primary outcome is the fraction of girls in each group who, direct after intervention, has decreased their maximum pain measured by Faces Pain Scale. Secondary outcomes are stress, psychical health, well-being, school and sleep functions, physical activity and health-economy. The study group will be followed up for two years. Just-in-TIME is an interdisciplinary research group with expertise in interventions for psychosomatic problems in children and adolescents. TIME, which stands for Try, Identify, Move and Enjoy, also characterizes this project, aiming at decreasing recurrent abdominal pain through an intervention with dance and yoga for 9-13 year old girls.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02920268
Study type Interventional
Source Region Örebro County
Contact
Status Active, not recruiting
Phase N/A
Start date April 2016
Completion date December 2023

See also
  Status Clinical Trial Phase
Completed NCT04677881 - Health Effects of Different Types of Bread N/A
Completed NCT02293343 - 24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance N/A
Completed NCT01717404 - Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C) Phase 1
Withdrawn NCT02313207 - Confocal Laser Endomicroscopy in IBS Patients N/A
Completed NCT02937506 - Patient Satisfaction With Propofol for Out Patient Colonoscopy Phase 4
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Completed NCT02419963 - Analyzing IBS to Identify Biomarkers and Microbiome Signatures N/A
Recruiting NCT06389851 - Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD N/A
Recruiting NCT05815602 - Ebastine Versus Mebeverine in IBS Patients Phase 3
Completed NCT03482765 - A Study of Probiotics in IBS Subjects N/A
Completed NCT03986476 - The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome N/A
Recruiting NCT06275906 - Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters. N/A
Not yet recruiting NCT05737277 - Gabapral in Pediatric IBS N/A
Active, not recruiting NCT05718505 - Comparison of the Atmo Motility Gas Capsule System to the Reference Standard N/A
Recruiting NCT06072287 - The Living With a Long-Term Condition Study
Completed NCT04953728 - Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C N/A
Completed NCT02681666 - Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome N/A
Completed NCT02981888 - Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome
Completed NCT01667627 - Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Phase 4
Recruiting NCT01779765 - The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Phase 4